Company
Headquarters: Suzhou, China
Employees: 745
CN¥13.80 Billion
CNY as of Jan. 1, 2024
US$1.94 Billion
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $461.52 B |
Vertex Pharmaceuticals Incorporated | $107.23 B |
Regeneron Pharmaceuticals, Inc. | $100.01 B |
CSL Limited | $94.74 B |
Marinomed Biotech AG | $73.23 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
BrightGene Bio-Medical Technology Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of medicines, and generic APIs and FDFs in China. Its product pipeline includes immuno-oncological therapeutic agents, orally available GLP-1RA peptides for type 2 diabetes, antibody drug conjugates for solid tumor, and novel non-antibody dependent tumor targeting conjugates for brain cancer and solid tumor brain-metastasis. The company also develops Eribulin, Trabectedin, Fondaparinux, Caspofungin, and non-biological molecules; macromolecules, such as Ferumoxytol and Ferric pyrophosphate citrate; and ADC cytotoxic payloads comprising Maytansinoids, Auristatins, and Calicheamicin. It offers cardiovascular, antibacterial, ADC, oncology, antifungal, iron supplement, anti-HBV, veterinary, and immuno products. The company was founded in 2001 and is based in Suzhou, China.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
BrightGene Bio-Medical Technology Co. Ltd has the following listings and related stock indices.
Stock: SSE: 688166 wb_incandescent